Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr Grivas on Key Data From the CheckMate 901 Trial in Urothelial Cancer

January 10th 2024

Petros Grivas, MD, PhD, discusses outcomes associated with the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

FDA Grants Breakthrough Therapy Designation to TAR-200 for BCG-Unresponsive High-Risk NMIBC

January 5th 2024

The FDA has granted breakthrough therapy designation to TAR-200 for use in the treatment of patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer who are not candidates for or opted not to receive radical cystectomy.

Dr Necchi on the Efficacy of TAR-200 Monotherapy in BCG-Unresponsive NMIBC

January 4th 2024

Andrea Necchi, MD, discusses results from the phase 2b SunRISe-1 trial of TAR-200 in patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer.

FDA Grants Fast Track, Breakthrough Therapy Designations to Cretostimogene Grenadenorepvec for NMIBC

January 3rd 2024

The FDA has granted fast track and breakthrough therapy designations to cretostimogene grenadenorepvec for use as a potential therapeutic option in patients with high-risk BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 tumors.

OncLive December Recap: FDA Approval Highlights

December 30th 2023

In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.

Revisit the Top 5 OncLive On Air Episodes of 2023

December 29th 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

EV-302 Regimen Bests Chemo in Advanced Urothelial Cancer

December 25th 2023

Findings from the EV-302 trial presented at the 2023 ESMO Congress revealed that the combination of enfortumab vedotin and pembrolizumab may become the preferred frontline standard of care for patients with locally advanced or metastatic urothelial cancer regardless of cisplatin eligibility.

ADCs and Immunotherapy Are Redefining Urothelial Cancer Treatment

December 21st 2023

Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer

December 15th 2023

The FDA has approved enfortumab vedotin in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

Enfortumab Vedotin/Pembrolizumab Combo, Maintenance Avelumab Continue as Gold Standards in Metastatic Urothelial Cancer

December 13th 2023

Lance C. Pagliaro, MD, highlights updated data from the JAVELIN Bladder 100 and EV-103 trials in metastatic urothelial carcinoma, discusses their relevance for navigating the expanding treatment armamentarium for this disease, and outlines several future avenues for research.

FDA Grants Priority Review to Frontline Nivolumab Plus Chemo for Unresectable or Metastatic Urothelial Carcinoma

December 5th 2023

The FDA has granted priority review to a supplemental biologics license application seeking the approval of nivolumab plus cisplatin-based chemotherapy as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma.

ADC Doublets Represent a Promising Novel Approach for Treatment-Resistant mUC

December 4th 2023

Bradley A. McGregor, MD, expands on the feasibility and safety considerations addressed through the design and methodology of the DAD study; highlights dose-limiting toxicities and early responses seen with sacituzumab govitecan plus enfortumab vedotin in treatment-resistant mUC; and explains how these results support further investigation of other ADC doublets.

Enfortumab Vedotin/Pembrolizumab Extends PFS and OS in Metastatic Urothelial Cancer

December 1st 2023

Thomas Powles, MD, MBBS, MRCP, discusses key background information about the EV-302 trial; the efficacy and safety findings from this trial; and the future implications of the data from several emerging trials in urothelial cancer.

Cretostimogene Grenadenorepvec Confers High CR Rate in NMIBC

December 1st 2023

Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

FDA Grants Priority Review to sBLA for Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

December 1st 2023

The FDA has granted priority review to a supplemental biologics license application for enfortumab vedotin plus pembrolizumab for the frontline treatment of patients with locally advanced or metastatic urothelial cancer.

Nadofaragene Firadenovec Induces Durable Activity in High-Risk, BCG-Unresponsive NMIBC With CIS

November 29th 2023

Nadofaragene firadenovec-vncg led to encouraging rates of high-grade recurrence-free survival and overall survival in patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Dr Sonpavde on the Efficacy of Frontline Nivolumab Plus Chemotherapy in Metastatic Urothelial Carcinoma

November 29th 2023

Guru P. Sonpavde, MD, discusses the significance of data from the phase 3 CheckMate 901 trial of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma.

Perioperative Enfortumab Vedotin Shows Antitumor Activity in Cisplatin-Ineligible MIBC

November 29th 2023

Perioperative enfortumab vedotin elicited responses in cisplatin-eligible patients with muscle-invasive bladder cancer.

Enfortumab Vedotin Plus Pembrolizumab Has Potential to Alter SOC in Frontline Urothelial Cancer

November 10th 2023

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

Dr Siefker-Radtke on the Efficacy of Erdafitinib vs Pembrolizumab in FGFR-Altered mUC

November 8th 2023

Arlene O. Siefker-Radtke, MD, discusses the efficacy of erdafitinib in patients with metastatic urothelial cancer with select FGFR alterations in the phase 3 THOR study.